Core Viewpoint - The stock of药捷安康-B (02617) experienced significant market interest, surging nearly 130% at one point during the day, ultimately closing up 77.09% at 192.5 HKD, with a total trading volume of 2.613 billion HKD and a turnover rate of approximately 4.74% [1] Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule innovative therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - As of June 30, 2025, the company has six clinical-stage candidate products and several preclinical candidates in its pipeline [1] Key Product Highlights - The core product,替恩戈替尼 (TT-00420), has garnered significant market attention due to multiple recent positive developments [1] - On September 10,替恩戈替尼 received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial in treating hormone receptor-positive (HR+) and HER2-negative or low-expressing recurrent or metastatic breast cancer [1] - The product is also involved in an open-label, multicenter Phase II clinical study for advanced hepatocellular carcinoma (HCC) in combination with 康方生物's 开坦尼/依达方, with the first patient recently dosed [1] - Additionally,替恩戈替尼 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer [1]
药捷安康-B尾盘回落收涨77.09% 全天成交额超26亿港元 换手率约4.74%